Home › Funds › Checkpoint Capital L.P. › RYTM

Checkpoint Capital L.P. position in RYTM

RHYTHM PHARMACEUTICALS INC · Health Care

Checkpoint Capital L.P. reported holding 1,216,574 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$115.8M, representing 26.19% of its reported portfolio and ranking #2 among its reported holdings. Checkpoint Capital L.P. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)1.22M sh
Reported value held$115.84M
Portfolio Weight26.19%
First reportedQ4 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Checkpoint Capital L.P.'s RYTM position evolved

Checkpoint Capital L.P. first disclosed a stake in RYTM in Q4 2023 at 730,000 shares (US$33.6M). The position peaked in Q2 2026 at 1,186,000 shares, worth US$131.7M. Across 12 filings, Checkpoint Capital L.P. increased the stake 8 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,216,574 shares valued at US$115.8M — an increase of 30,574 shares quarter over quarter.. Notable position changes include a 28% trim in Q3 2024 (shares rose 7% over the following quarter), a 28% trim in Q3 2025 (shares rose 6% over the following quarter), a 30% increase in Q4 2025 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 730.00K $33.56M New
Q1 2024 825.50K $35.77M Add
Q2 2024 922.10K $37.86M Add
Q3 2024 663.38K $34.75M Reduce
Q4 2024 727.98K $40.75M Add
Q1 2025 907.24K $48.06M Add
Q2 2025 1.06M $66.98M Add
Q3 2025 763.71K $77.13M Reduce
Q4 2025 992.20K $106.21M Add
Q1 2026 1.23M $106.73M Add
Q2 2026 1.19M $131.68M Reduce
Q3 2026 1.22M $115.84M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RYTM and 13F data

RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 40 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RYTM

All RYTM fund holders →

FAQ

How long has Checkpoint Capital L.P. held RYTM?

Checkpoint Capital L.P. has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Checkpoint Capital L.P.'s current position in RYTM?

As of Q3 2026, Checkpoint Capital L.P. holds 1.22M shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $115.84M, representing 26.19% of its reported portfolio and ranking #2.

Has Checkpoint Capital L.P. been buying or selling RYTM?

In the latest 13F filing (Q3 2026), Checkpoint Capital L.P. increased its position in RYTM. The position peaked in Q2 2026 at 1.19M shares.

Which other funds hold RYTM?

Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 40 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.